Lilly's Asset Management Program
Executive Summary
Eli Lilly & Co.'s recent explosion of dealmaking in the seemingly disparate areas of combinatorial chemistry and drug delivery are in fact closely linked by Lilly's approach towards asset management.
You may also be interested in...
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
QUOTED. Harel Gadot.
Medtech Insight talked with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and market opportunities. See what Gadot said about the market opportunity here.
Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.